###begin article-title 0
###xml 105 113 <span type="species:ncbi:9606">patients</span>
Reduced IgG anti-small nuclear ribonucleoprotein autoantibody production in systemic lupus erythematosus patients with positive IgM anti-cytomegalovirus antibodies
###end article-title 0
###begin p 1
This is an open access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Introduction
###end title 2
###begin p 3
###xml 171 189 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 241 259 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 278 281 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 405 408 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 514 517 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 610 613 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Systemic lupus erythematosus is characterized by production of autoantibodies to RNA or DNA-protein complexes such as small nuclear ribonucleoproteins (snRNPs). A role of Epstein-Barr virus in the pathogenesis has been suggested. Similar to Epstein-Barr virus, cytomegalovirus (CMV) infects the majority of individuals at a young age and establishes latency with a potential for reactivation. Homology of CMV glycoprotein B (UL55) with the U1snRNP-70 kDa protein (U1-70 k) has been described; however, the role of CMV infection in production of anti-snRNPs is controversial. We investigated the association of CMV serology and autoantibodies in systemic lupus erythematosus.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 278 279 275 276 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 18 26 <span type="species:ncbi:9606">patients</span>
###xml 77 80 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 85 103 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Sixty-one Mexican patients with systemic lupus erythematosus were tested for CMV and Epstein-Barr virus serology (viral capsid antigen, IgG, IgM) and autoantibodies by immunoprecipitation and ELISA (IgG and IgM class, U1RNP/Sm, U1-70 k, P peptide, rheumatoid factor, dsDNA, beta2-glycoprotein I).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 765 767 765 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 780 782 780 782 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 949 951 949 951 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1083 1085 1083 1085 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 9 12 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 26 29 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 186 189 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 228 231 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 301 304 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 328 331 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 390 393 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 492 510 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 678 681 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 882 885 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 984 987 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
IgG anti-CMV and IgM anti-CMV were positive in 95% (58/61) and 33% (20/61), respectively, and two cases were negative for both. Clinical manifestation and autoantibodies in the IgM anti-CMV(+) group (n = 20) versus the IgM anti-CMV(-)IgG (+) (n = 39) group were compared. Most (19/20) of the IgM anti-CMV(+) cases were IgG anti-CMV(+), consistent with reactivation or reinfection. IgM anti-CMV was unrelated to rheumatoid factor or IgM class autoantibodies and none was positive for IgM anti-Epstein-Barr virus-viral capsid antigen, indicating that this is not simply due to false positive results caused by rheumatoid factor or nonspecific binding by certain IgM. The IgM anti-CMV(+) group has significantly lower levels of IgG anti-U1RNP/Sm and IgG anti-U1-70 k (P = 0.0004 and P = 0.0046, respectively). This finding was also confirmed by immunoprecipitation. Among the IgM anti-CMV(-) subset, anti-Su was associated with anti-U1RNP and anti-Ro (P < 0.05). High levels of IgG anti-CMV were associated with production of lupus-related autoantibodies to RNA or DNA-protein complex (P = 0.0077).
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 41 44 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Our findings suggest a potential role of CMV in regulation of autoantibodies to snRNPs and may provide a unique insight to understand the pathogenesis.
###end p 9
###begin title 10
Introduction
###end title 10
###begin p 11
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 450 451 450 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 798 799 798 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 800 801 800 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 862 863 862 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 962 963 962 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1075 1076 1075 1076 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1147 1148 1147 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1149 1150 1149 1150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1151 1152 1151 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 1363 1364 1363 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1365 1367 1365 1367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1590 1592 1590 1592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1593 1595 1593 1595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1666 1668 1666 1668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1669 1671 1669 1671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 523 531 <span type="species:ncbi:9606">patients</span>
###xml 634 652 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 654 657 <span type="species:ncbi:10376">EBV</span>
###xml 677 680 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 687 701 <span type="species:ncbi:10798">parvovirus B19</span>
###xml 828 831 <span type="species:ncbi:10376">EBV</span>
###xml 852 860 <span type="species:ncbi:9606">patients</span>
###xml 878 881 <span type="species:ncbi:10376">EBV</span>
###xml 1166 1169 <span type="species:ncbi:10376">EBV</span>
###xml 1171 1174 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1397 1400 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1438 1441 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1456 1459 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1510 1518 <span type="species:ncbi:9606">patients</span>
###xml 1633 1636 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown etiology, characterized by production of autoantibodies to cellular constituents - in particular, complexes of dsDNA or RNA and proteins [1]. Various genetic and environmental factors appear to be involved in the development of SLE and the production of autoantibodies. Among the environmental factors, a role of viruses in triggering SLE has been investigated for many years [2,3]. However, traditional approaches to identify unique viruses among SLE patients did not produce consistent results, however, and recent evidence suggests that common viruses such as Epstein-Barr virus (EBV), cytomegalovirus (CMV), and parvovirus B19, to which many individuals are exposed during life, may play a role in the pathogenesis of SLE [2,3]. Increased prevalence of EBV infection among SLE patients [4], homology of EBV nuclear antigen (EBNA) 1 antigen and small nuclear ribonucleoproteins (snRNPs) [5], the pattern of epitope spreading consistent with molecular mimicry mechanism of induction of autoantibodies [6], and supporting evidence from animal models have all been described [5,7,8]. Similar to EBV, CMV infects the majority of individuals at a young age and establishes lifelong latency with possible reactivation at various times caused by a variety of triggers such as acute inflammation [9,10]. The reported prevalence of CMV infection based on detection of anti-CMV antibodies or CMV-DNA by PCR analysis of whole blood samples in SLE patients is from 60% to 100% similar to the control population in most studies [11,12]. A new infection or reactivation of CMV can mimic SLE in some cases [12,13].
###end p 11
###begin p 12
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 83 86 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 182 187 <span type="species:ncbi:10090">mouse</span>
###xml 258 261 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 300 308 <span type="species:ncbi:9606">patients</span>
Previous studies have shown a homology of the U1snRNP-70 kDa protein (U1-70 k) and CMV envelope glycoprotein B (UL55) and induction of anti-U1-70 k antibodies by glycoprotein B in a mouse model [14,15]. Association between autoantibodies to the U1snRNPs and CMV infection in healthy subjects and SLE patients has been reported [11]; however, this was not confirmed in another study [16].
###end p 12
###begin p 13
###xml 72 75 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
In the present study, we investigated whether the serological status of CMV infection has an association with the production of specific lupus autoantibodies - in particular, antibodies to snRNPs.
###end p 13
###begin title 14
Materials and methods
###end title 14
###begin title 15
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 15
###begin p 16
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 22 30 <span type="species:ncbi:9606">patients</span>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
Sixty-one consecutive patients with SLE from the Department of Rheumatology, Hospital General de Occidente, Zapopan, Jalisco, Mexico were studied. All patients fulfilled the 1982 American College of Rheumatology SLE classification criteria [17].
###end p 16
###begin p 17
###xml 217 219 217 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 220 222 220 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
The Mexican Systemic Lupus Erythematosus Disease Activity Index and the Systemic Lupus International Collaborating Clinics/American Collage of Rheumatology Damage Indexes at the beginning of the study were evaluated [18,19]. A complete blood count, including the lymphocyte count and serum rheumatoid factor (RF) (CELL-DYN 3500R; Abbott Diagnostics (Santa Clara, CA, USA), was determined in all subjects. Information on treatment on the day of sampling, including use of immunosuppressive drugs (azathioprine, methotrexate, and cyclophosphamide), chloroquine, and a dose of steroid (prednisone mg/day), was recorded.
###end p 17
###begin p 18
###xml 197 205 <span type="species:ncbi:9606">patients</span>
The protocol was approved by the Institutional Review Board. The present study meets and is in compliance with all ethical standards in medicine, and written informed consent was obtained from all patients according to the Declaration of Helsinki.
###end p 18
###begin title 19
Viral serology
###end title 19
###begin p 20
###xml 31 34 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 295 298 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 352 355 <span type="species:ncbi:10376">EBV</span>
IgG and IgM antibodies against CMV were measured using a microparticle enzyme immunoassay kit (Abbott Laboratories, Abbott Park, IL, USA) following the manufacturer's instructions. The specimens with index values >/= 0.5 units/ml and >/= 15 units/ml, respectively, for IgM and IgG antibodies to CMV, were considered positive. IgG and IgM antibodies to EBV viral capsid antigen (VCA) were measured by ELISA (Biotech Atlantic Inc., Eatontown, NJ, USA).
###end p 20
###begin title 21
Anti-U1RNP/Sm antigen-capture ELISA
###end title 21
###begin p 22
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 255 257 245 247 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2a</sub>
###xml 274 276 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 507 508 496 497 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 1620 1622 1609 1611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 85 90 <span type="species:ncbi:9606">human</span>
###xml 236 241 <span type="species:ncbi:10090">mouse</span>
###xml 1001 1006 <span type="species:ncbi:10090">mouse</span>
###xml 1238 1243 <span type="species:ncbi:10090">mouse</span>
###xml 1252 1257 <span type="species:ncbi:9606">human</span>
Anti-U1RNP/Sm antigen-capture ELISA was performed essentially as described for other human autoantibody systems [20]. Briefly, microtiter plates (Immobilizer Aminotrade mark; Nalgene Nunc [Rochester, NY, USA]) were coated with 3 mug/ml mouse mAb 2.73 (IgG2a, anti-U1-70 k) [21] overnight and were blocked with 0.5% BSA NET/NP40 (150 mM NaCl, 2 mM ethylenediamine tetraacetic acid, 50 mM Tris-HCl, pH 7.5, 0.3% Nonidet-P40). The left half of the plate was incubated with K562 cell lysate (50 mul/well, 4 x 107/ml) and the right half was incubated with the blocking buffer. After washing the plate with Tris-buffered saline/Tween20 (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1% Tween20) three times and 0.5 M NaCl/NET/NP40 (500 mM NaCl, 2 mM ethylenediamine tetraacetic acid, 50 mM Tris-HCl, pH 7.5, 0.3% Nonidet-P40) three times, an identical set of samples and serially diluted standard serum (1:500 to serial 1:5 dilutions) were added to the left half and the right half (control for reactivity against mouse IgG) of the plate. Serum samples were tested at 1:500 and 1:2,500 dilutions, and data from the latter were used for the analysis. Plates were washed with Tris-buffered saline/Tween20, incubated with alkaline phosphatase-conjugated mouse mAbs to human IgG (1:1,000 dilution; Sigma [St. Louis, MO, USA]) and developed. The 405 nm optical density of wells were converted into units based on the standard curve using SoftMax Pro 4.3 software (Molecular Devices, Sunnyvale, CA, USA) and the units of the corresponding right half (without U1RNP/Sm antigens) were subtracted from those of the left half (with antigens) [20].
###end p 22
###begin title 23
###xml 90 91 87 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 42 47 <span type="species:ncbi:10090">mouse</span>
ELISA for antibodies to P peptide, dsDNA, mouse IgG (rheumatoid factor), U1-70 k, and beta2-glycoprotein I
###end title 23
###begin p 24
###xml 373 375 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 446 448 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 487 489 477 479 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 496 499 486 489 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2a </sub>
###xml 653 655 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 662 663 649 650 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 428 433 <span type="species:ncbi:9606">human</span>
###xml 451 456 <span type="species:ncbi:10090">Mouse</span>
###xml 478 483 <span type="species:ncbi:10090">mouse</span>
Microtiter plates (Immobilizer Aminotrade mark; Nunc) were incubated with 1 to 3 mug/ml appropriate antigen, and ELISA was performed as described previously using 1:500 (for all IgG class antibodies), 1:2,500 (IgG anti-U1-70 k ELISA) or 1:100 (for all IgM class antibodies) diluted sera. Optical densities were converted into units as described using appropriate standard [20]. P peptide was the COOH-terminal 22 amino acids of human P0 protein [22]. Mouse IgG was a mixture of mouse IgG1 and IgG2a myeloma proteins (Southern Biotechnology, Birmingham, AL, USA). dsDNA was purified using S1 nuclease and the ELISA was performed as described previously [20]. beta2-glycoprotein I was a gift from Dr Jyunichi Kaburaki (Tokyo Electric Company Hospital, Tokyo, Japan).
###end p 24
###begin p 25
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 520 537 520 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli </italic>
###xml 99 104 <span type="species:ncbi:9606">human</span>
###xml 520 536 <span type="species:ncbi:562">Escherichia coli</span>
U1-70 k recombinant protein was a 184 amino acid fragment spanning amino acids 240 to 423, a major human B-cell epitope that contains the arginine/serine-rich region [23]. The full-length cDNA for U1-70 k protein was kindly provided by Dr Ger JM Pruijn (Department of Biochemistry, University of Nijmegen, The Netherlands). The cDNA fragment was cloned by PCR amplification and subcloned into pDONR transition vector (Invitrogen, Carlsbad, CA, USA) and then into pDEST17 vector. The recombinant protein was expressed in Escherichia coli and purified via nickel affinity column.
###end p 25
###begin title 26
###xml 31 36 <span type="species:ncbi:9606">human</span>
Screening of autoantibodies in human sera by immunoprecipitation
###end title 26
###begin p 27
###xml 26 28 26 28 <sup xmlns:xlink="http://www.w3.org/1999/xlink">35</sup>
###xml 122 124 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 380 382 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 544 546 543 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
Immunoprecipitation using 35S-methionine-labeled K562 cell extract was performed using 8 mul sera as described elsewhere [21]. Specificities were determined using previously described reference sera. Positive anti-U1RNP was defined based on the presence of the set of U1RNP proteins (A, B'/B, C, D1/D2/D3, E/F, and G). Since autoantibodies to U5RNP without anti-Sm are very rare [24], immunoprecipitation of the characteristic U5RNP 200 kDa proteins was used to define anti-Sm (which immunoprecipitates U2, U4-U6, and U5 in addition to U1RNP) [21].
###end p 27
###begin title 28
Statistical analysis
###end title 28
###begin p 29
All statistical analysis was performed using Prism 5.0 for Macintosh (GraphPad Software, Inc., San Diego, CA, USA). Fisher's exact test and the Mann-Whitney test were used to analyze the prevalence and the levels, respectively, of autoantibodies and other data.
###end p 29
###begin title 30
Results
###end title 30
###begin title 31
Cytomegalovirus serology
###end title 31
###begin p 32
###xml 434 435 434 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 36 39 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 73 76 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 276 284 <span type="species:ncbi:9606">patients</span>
###xml 341 344 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 410 413 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
The prevalence of positive IgG anti-CMV antibodies and positive IgM anti-CMV antibodies in the SLE population was 95% (58/61) and 33% (20/61), respectively. Two subjects, negative for both IgG and IgM antibodies, were excluded from the following analysis. The rest of the SLE patients were divided into two groups; 20 subjects who were anti-CMV IgM(+) [19 IgG(+) and one IgG(-)], and 39 subjects who were anti-CMV IgM(-)IgG(+) (Table 1).
###end p 32
###begin p 33
###xml 73 81 <span type="species:ncbi:9606">patients</span>
###xml 96 99 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 119 122 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Demographic and clinical characteristics in systemic lupus erythematosus patients with IgM anti-CMV(+) versus IgM anti-CMV(-)
###end p 33
###begin p 34
###xml 232 234 230 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 263 265 261 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 303 305 301 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 457 458 455 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 528 529 526 527 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 118 121 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 148 151 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 315 318 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 504 512 <span type="species:ncbi:9606">patients</span>
Data presented as the mean +/- standard deviation (minimum to maximum). All values were compared between the IgM anti-CMV(+) group and the IgM anti-CMV(-)IgG(+) group using the Mann-Whitney test (values) or Fisher's exact test (%). P values were not significant (P > 0.05) except for age at diagnosis (*P = 0.048). CMV, cytomegalovirus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; SLICC, Systemic Lupus International Collaborating Clinics. aInformation for treatment was available in 19 patients in this group. bAzathioprine, methotrexate, or cyclophosphamide.
###end p 34
###begin title 35
Demographic and clinical characteristics
###end title 35
###begin p 36
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 313 315 311 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 84 87 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 117 120 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 175 183 <span type="species:ncbi:9606">patients</span>
###xml 299 302 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 437 445 <span type="species:ncbi:9606">patients</span>
The demographic and clinical characteristics of the subjects comparing the IgM anti-CMV(+) group versus the IgM anti-CMV(-)IgG(+) group are summarized in Table 1. Of these 59 patients, 56 were female and three were male with mean age of 36.7 +/- 14.1 years. Age at onset was younger in the IgM anti-CMV(+) group (P < 0.05 by Mann-Whitney test) but otherwise no significant differences were observed between the groups. The percentage of patients on immunosuppressive drugs (azathioprine, methotrexate, and cyclophosphamide), on chloroquine, or on steroids, and a dose of steroids (prednisone mg/day) also was not significantly different between groups.
###end p 36
###begin title 37
###xml 9 12 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
IgM anti-CMV antibodies are not due to rheumatoid factor or nonspecific reactivity of certain IgM antibodies
###end title 37
###begin p 38
###xml 86 87 86 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 9 12 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 81 84 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 120 123 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
###xml 298 301 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 312 320 <span type="species:ncbi:9606">patients</span>
###xml 366 369 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
IgM anti-CMV can become positive in some cases of reactivation or reinfection of CMV [9,10]. The prevalence of IgM anti-CMV among SLE patients in the present study was much higher (33%) than in the general population, similar to some previous studies that also reported high prevalence of IgM anti-CMV among SLE patients [25-27]. False positive results for IgM anti-CMV due to RF or nonspecific binding of certain IgM antibodies, however, have also been reported [25].
###end p 38
###begin p 39
###xml 151 152 151 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 552 553 549 550 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 577 578 574 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 95 98 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 102 110 <span type="species:ncbi:9606">patients</span>
###xml 127 130 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
###xml 218 226 <span type="species:ncbi:9606">patients</span>
###xml 248 251 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 365 368 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 398 401 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 450 453 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 672 675 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 715 718 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 722 730 <span type="species:ncbi:9606">patients</span>
###xml 745 748 <span type="species:ncbi:10376">EBV</span>
###xml 820 823 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 916 924 <span type="species:ncbi:9606">patients</span>
###xml 939 942 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 955 963 <span type="species:ncbi:9606">patients</span>
###xml 1042 1045 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1072 1080 <span type="species:ncbi:9606">patients</span>
###xml 1147 1150 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
The levels of RF and other control IgM autoantibodies were therefore compared between IgM anti-CMV(+) patients versus IgM anti-CMV(-) patients (Figure 1) to examine whether RF or nonspecific reaction of IgM in certain patients can explain IgM anti-CMV in our cohort. Levels of RF by laser nephelometry and of IgM and IgG RF by ELISA were not higher in the IgM anti-CMV(+) group versus the IgM anti-CMV(-) group, indicating that the positive IgM anti-CMV is not simply due to RF in this group. Furthermore, levels of IgM antibodies to U1-70 k or to beta2-glycoprotein I (Figure 1), dsDNA, P peptide, U1RNP/Sm, and chromatin (data not shown) were not higher in the IgM anti-CMV(+) group. In addition, all 20 IgM anti-CMV(+) patients were IgM anti-EBV viral capsid antigen-negative, indicating that high levels of IgM anti-CMV in this group are not due to nonspecific high reactivity of IgM antibodies in this group of patients. The IgM anti-CMV(+) group of patients was therefore considered to mainly reflect the reactivation or reinfection of CMV, and possibly some of the patients may be at a late stage of primary infection [one subject was anti-CMV IgM(+)IgG(-)].
###end p 39
###begin p 40
###xml 311 312 308 309 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 67 70 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 86 89 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 93 101 <span type="species:ncbi:9606">patients</span>
###xml 129 132 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 240 245 <span type="species:ncbi:10090">mouse</span>
###xml 478 483 <span type="species:ncbi:10090">mouse</span>
Serum rheumatoid factor and other IgM class antibodies in IgM anti-CMV(+) versus anti-CMV(-) patients. IgM anti-cytomegalovirus (CMV) (microparticle enzyme immunoassay), rheumatoid factor (RF) (laser nephelometry), IgM or IgG antibodies to mouse IgG, IgM anti-U1snRNP-70 kDa protein (anti-U1-70 k) and anti-beta2-glycoprotein I (anti-beta2GPI) (ELISA) were performed as described in Materials and methods. Serum dilution for ELISA was 1:100 for IgM class and 1:500 for IgG anti-mouse IgG.
###end p 40
###begin title 41
###xml 48 51 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 71 74 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Prevalence and levels of autoantibodies in anti-CMV IgM(+) versus anti-CMV IgM(-)IgG(+) groups
###end title 41
###begin p 42
###xml 315 316 315 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 703 705 703 705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 922 924 922 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 60 63 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 93 96 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 108 111 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 203 206 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 426 429 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 476 479 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 629 632 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 662 665 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 677 680 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 863 866 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 886 889 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
The prevalence and levels of autoantibodies in the IgM anti-CMV(+) group versus the IgM anti-CMV(-)IgG anti-CMV(+) group were compared by immunoprecipitation and ELISA to evaluate the association of the CMV serology and autoantibodies. The prevalence of autoantibodies by immunoprecipitation is summarized in Table 2. In general, the prevalence of autoantibodies was similar except that anti-Sm was found only in the IgM anti-CMV(-) group (15%, 6/39) and none in the IgM anti-CMV(+) group (0/20, not significant). The prevalence of anti-Sm among the anti-U1snRNP-positive subset, however, was significantly lower in the IgM anti-CMV(+) group versus the IgM anti-CMV(-)IgG anti-CMV(+) group (0% vs. 50%, P = 0.04 by Fisher's exact test). Furthermore, the prevalence of high levels (>25 units) of antibodies to U1RNP/Sm by ELISA was significantly lower in the anti-CMV IgM(+) versus anti-CMV IgM(-)IgG(+) group (0% vs. 28%, P = 0.0106 by Fisher's exact test).
###end p 42
###begin p 43
###xml 57 60 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 90 93 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 97 105 <span type="species:ncbi:9606">patients</span>
Frequency of autoantibodies in IgM anti-cytomegalovirus (CMV)(+) patients versus IgM anti-CMV(-) patients
###end p 43
###begin p 44
###xml 69 71 69 71 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 79 85 79 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</sup>
###xml 85 87 80 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Sm/U1RNP, prevalence of anti-Sm among anti-U1RNP-positive patients. *P = 0.04. daggerP = 0.0106.
###end p 44
###begin p 45
###xml 272 274 272 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 356 358 356 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 393 395 393 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 518 519 518 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 831 832 828 829 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 856 858 853 855 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 907 908 904 905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 123 126 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 153 156 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 168 171 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 286 289 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 425 428 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
To confirm the difference in levels of autoantibodies to snRNPs, anti-snRNP immunoprecipitation-positive samples (IgM anti-CMV(+) group, n = 7; IgM anti-CMV(-)IgG anti-CMV(+) group, n = 12) were tested by anti-U1RNP/Sm antigen-capture ELISA and anti-U1-70 k ELISA (Figure 2a). The anti-CMV IgM(+) group has significantly lower levels of IgG anti-U1RNP/Sm (P = 0.0004) and of IgG anti-U1-70 k (P = 0.0046) versus the IgM anti-CMV(-)IgG(+) group. Levels of IgM anti-U1RNP/Sm (data not shown) or IgM anti-U1-70 k (Figure 1, bottom left) were not significantly different between groups, indicating that this is a phenomenon specific for IgG class antibodies. Furthermore, this is specific for IgG anti-U1RNP/Sm and U1-70 k and is not a general phenomenon of IgG-class autoantibodies, since the levels of IgG anti-P peptide, dsDNA, beta2-glycoprotein I (Figure 2b), or IgG RF were similar between groups (Figure 1).
###end p 45
###begin p 46
###xml 80 84 80 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 431 435 431 435 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 484 485 481 482 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 40 43 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 63 66 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
###xml 306 309 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 344 347 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
IgG autoantibodies by ELISA in IgM anti-CMV(+) versus IgM anti-CMV(-) patients. (a) IgG anti-U1RNP/Sm and IgG anti-U1snRNP-70 kDa protein (anti-U1-70 k) by ELISA. Anti-small nuclear ribonucleoprotein (Anti-snRNP) immunoprecipitation-positive sera (1:2,500 dilution, n = 7 for the IgM anti-cytomegalovirus (CMV)(+) group and n = 12 for the anti-CMV IgM(-)IgG(+) group) were tested for anti-U1RNP/Sm and U1-70 k antibodies by ELISA. (b) IgG anti-U1-70 k, P peptide, dsDNA, and anti-beta2-glycoprotein I (anti-beta2GPI) by ELISA. ELISAs were performed as described in Materials and methods using 1:500 diluted sera. For anti-U1RNP/Sm and U1-70 k, data from 1:2,500 diluted sera are shown.
###end p 46
###begin p 47
###xml 72 73 72 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 350 352 350 352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 211 214 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 283 286 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 512 515 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 545 548 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Levels of anti-snRNPs were also compared by immunoprecipitation (Figure 3). Although all components of U1snRNPs (A, B'/B, C, D1/D2/D3, E/F, and G) were seen by all seven anti-snRNP-positive sera in the IgM anti-CMV(+) group, signals were much weaker than those by sera from the anti-CMV IgM(-)IgG (+) group, consistent with the ELISA results (Figure 2a). Signals of other autoantibodies by immunoprecipitation - including anti-Ro, ribosomal P, RNA helicase A, and Su - were not clearly different in the IgM anti-CMV(+) group versus the IgM anti-CMV(-)IgG(+) group, consistent with the ELISA data.
###end p 47
###begin p 48
###xml 230 233 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 315 318 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 352 357 <span type="species:ncbi:9606">human</span>
Autoantibodies to small nuclear ribonucleoproteins by immunoprecipitation. Immunoprecipitation by anti-small nuclear ribonucleoprotein immunoprecipitation-positive sera (lanes 1 to 7, all seven sera from the anti-cytomegalovirus (CMV) IgM(+) group; lanes 8 to 13, six randomly selected sera from the 12 in the anti-CMV IgM(-)IgG(+) group) and a normal human serum (NHS) are shown. Positions of UsnRNP components A, B'/B, C, D1/D2/D3, E/F, G, U5-200 k doublet, and 60 k Ro, and molecular weights (kDa) are indicated. White arrowheads, U5-200 k.
###end p 48
###begin p 49
###xml 42 45 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
All these data indicate that the IgM anti-CMV(+) group has lower levels of IgG autoantibodies specifically for anti-U1RNP/Sm and U1-70 k; however, no difference was observed in IgM-class autoantibodies for these specificities or other autoantibodies in the IgG or IgM class.
###end p 49
###begin title 50
###xml 53 56 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 72 75 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Relationship of different autoantibodies in the anti-CMV IgM(+) and ant-CMV IgM(-)IgG(+) groups
###end title 50
###begin p 51
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 484 486 484 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 499 501 499 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 569 570 569 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 728 730 728 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 922 924 922 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 58 61 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 85 88 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 336 339 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 460 463 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 545 548 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 752 755 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 947 950 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1055 1058 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1081 1089 <span type="species:ncbi:9606">patients</span>
Although the prevalence of various autoantibodies in anti-CMV IgM(+) SLE versus anti-CMV IgM(-)IgG(+) SLE was similar (Table 2), it is possible that the pattern of coexistence of autoantibodies is different. The prevalence of various autoantibodies in anti-U1RNP, Ro, or Su positive versus negative subsets and the presence of IgM anti-CMV antibodies were therefore analyzed. Anti-Su antibodies appeared to frequently coexist with anti-U1RNP or Ro in the anti-CMV IgM(-)IgG(+) group (P = 0.0141 and P = 0.0631, respectively) but not in the anti-CMV IgM(+) group (Table 3). When similar analysis was performed for anti-U1RNP(+) versus anti-U1RNP(-), anti-Su was found in 50% (6/12) of the former versus 11% (3/27) of the latter (P = 0.0141) in the anti-CMV IgM(-)IgG(+) subset. Similarly, anti-Su appeared to be more frequent for anti-Ro(+) than anti-Ro(-), although it did not reach statistical significance (40% vs. 13%, P = 0.0631), in the anti-CMV IgM(-)IgG(+) group. Anti-Su and anti-U1RNP or anti-Ro may therefore coexist frequently only in the anti-CMV IgM(-)IgG(+) group of patients.
###end p 51
###begin p 52
Association of anti-Su and other autoantibodies
###end p 52
###begin p 53
###xml 23 25 23 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 35 41 35 36 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</sup>
###xml 41 43 36 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 0 3 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
CMV, cytomegalovirus. *P = 0.0141, daggerP = 0.0631.
###end p 53
###begin title 54
###xml 19 22 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Levels of IgG anti-CMV antibodies and presence of autoantibodies
###end title 54
###begin p 55
###xml 295 296 295 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 436 438 436 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 643 645 643 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 85 88 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 124 127 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 177 180 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 326 329 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 520 523 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 620 623 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 810 818 <span type="species:ncbi:9606">patients</span>
###xml 848 851 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Seventy-seven percent (47/61) of cases had very high levels (>250 units) of IgG anti-CMV; 89% (54/61) of cases had IgG anti-CMV > 200 units, while only seven cases had IgG anti-CMV < 200 units. The prevalence of autoantibodies by immunoprecipitation was compared between these two groups (Table 4). The latter group (IgG anti-CMV < 200 units) had only one each of anti-Ro and anti-Su, and none in this group had anti-U1RNP (0% vs. 35%, P = 0.0875), Sm, ribosomal P, RNA helicase A, La, and Ku. Only 28% in this IgG anti-CMV < 200 units group had any of the above listed autoantibodies versus 81% (44/54) in the IgG anti-CMV > 200 units group (P = 0.0077 by Fisher's exact test), indicating that the production of IgG lupus-related autoantibodies to RNA or dsDNA-protein complexes is generally more frequent in patients with high levels of IgG anti-CMV.
###end p 55
###begin p 56
###xml 61 64 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 66 74 <span type="species:ncbi:9606">patients</span>
###xml 96 99 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 100 108 <span type="species:ncbi:9606">patients</span>
Frequency of autoantibodies in low IgG anti-cytomegalovirus (CMV) patients versus high IgG anti-CMV patients
###end p 56
###begin p 57
###xml 1 3 1 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 13 19 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</sup>
###xml 19 21 14 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
*P = 0.0875, daggerP = 0.0077 by Fisher's exact test.
###end p 57
###begin title 58
Discussion
###end title 58
###begin p 59
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 458 459 458 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 670 672 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 676 678 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 8 11 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 89 92 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 113 116 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 266 269 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 292 295 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 345 348 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 377 380 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 408 416 <span type="species:ncbi:9606">patients</span>
###xml 453 456 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 468 471 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 555 563 <span type="species:ncbi:9606">patients</span>
###xml 626 629 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 764 767 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 802 805 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
SLE and CMV infection share common manifestations and a new infection or reactivation of CMV can mimic SLE [28]. CMV may also be considered responsible for flare or development of SLE in some cases [13,28-31]. Primary infection is characterized by positive IgM anti-CMV and negative IgG anti-CMV, followed by seroconversion to positive IgG anti-CMV; however, positive IgM anti-CMV is also seen frequently in patients with reactivation or reinfection of CMV [9,10,32]. CMV infection is a common complication in the immunocompromised host and in transplant patients under immunosuppressive therapy [10]. Whether reactivation of CMV is also common in SLE is controversial [25-27,33], because of a lack of standardized methods leading to inconsistency in the IgM anti-CMV assay and the PCR assay to detect CMV DNA.
###end p 59
###begin p 60
###xml 192 194 192 194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 195 197 195 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 201 203 201 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 204 206 204 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
###xml 56 59 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 73 76 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 128 136 <span type="species:ncbi:9606">patients</span>
###xml 278 281 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 289 297 <span type="species:ncbi:9606">patients</span>
In the present study, 95% of SLE patients were IgG anti-CMV(+). IgG anti-CMV detected at a high percentage (60% to 100%) in SLE patients was similar to the control population in most studies [11,25-27,34,35], although a few studies have reported a higher percentage of IgG anti-CMV in SLE patients versus control individuals [12,36].
###end p 60
###begin p 61
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 83 85 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 86 88 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 348 350 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 561 563 561 563 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 572 574 572 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 852 854 852 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1038 1039 1038 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 1338 1339 1335 1336 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1377 1378 1374 1375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 36 39 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 161 164 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 257 260 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 388 391 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 481 484 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 528 536 <span type="species:ncbi:9606">patients</span>
###xml 685 688 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 760 763 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 789 792 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 800 808 <span type="species:ncbi:9606">patients</span>
###xml 902 905 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 968 971 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1118 1121 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1166 1169 <span type="species:ncbi:10376">EBV</span>
###xml 1228 1231 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1406 1409 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1460 1468 <span type="species:ncbi:9606">patients</span>
###xml 1495 1498 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1540 1543 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1619 1622 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1671 1674 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
The reported prevalence of IgM anti-CMV varies significantly from 5% to 45% [12,25-27,34], and was 33% in the present study. False positive results for IgM anti-CMV due to RF and other reasons have been reported [25-27]. In one study that reported IgM anti-CMV in 14% of SLE cases, 3/12 were considered an artifact after a RF neutralization assay [27]. Other studies interpreted IgM anti-CMV as false positive results based on negative PCR [25,26]. In contrast, one study detected CMV DNA by PCR in whole blood from 100% of SLE patients versus 72% in controls (P = 0.02) [12], suggesting a significant difference in sensitivity of the PCR assay. A recent study using immunostaining of CMV pp65 in peripheral blood leukocytes has suggested that reactivation of CMV is common among IgM anti-CMV(+) SLE patients under intensive immunosuppressive therapy [33]. The RF neutralization assay or PCR to detect CMV DNA was not performed in the present study; however, IgM anti-CMV was not associated with RF by laser nephelometry or ELISA (Figure 1), suggesting it was not directly due to RF. Furthermore, none of the IgM anti-CMV(+) group was positive for IgM antibodies to EBV-viral capsid antigen (data not shown). Also, the IgM anti-CMV(+) group did not have higher levels of IgM class autoantibodies to snRNPs, U1-70 k, dsDNA, chromatin, beta2-glycoprotein I, or P peptide (Figure 1), indicating that IgM anti-CMV was not due to nonspecific IgM reactions in these patients. The majority of IgM anti-CMV therefore appears to be specific for the CMV assay and may be considered a reflection of reactivation or reinfection of CMV since all except one case had positive IgG anti-CMV.
###end p 61
###begin p 62
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 464 466 464 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 467 469 467 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 733 735 733 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 736 738 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 881 883 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 884 886 884 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1142 1144 1142 1144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1576 1578 1576 1578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 50 58 <span type="species:ncbi:9606">patients</span>
###xml 325 333 <span type="species:ncbi:9606">patients</span>
###xml 343 346 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 451 456 <span type="species:ncbi:10090">mouse</span>
###xml 472 477 <span type="species:ncbi:9606">Human</span>
###xml 540 543 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 644 647 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 811 814 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 853 861 <span type="species:ncbi:9606">patients</span>
###xml 978 981 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1199 1202 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1403 1406 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1436 1439 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1533 1536 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1561 1564 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1655 1658 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1676 1684 <span type="species:ncbi:9606">patients</span>
Autoantibodies to snRNPs are found in ~40% of SLE patients, in 100% of mixed connective tissue disease and at lower prevalence in other systemic rheumatic diseases [37]. The autoimmune response to U1-70 k is considered characteristic of mixed connective tissue disease and an early autoimmune response in anti-U1RNP-positive patients [37,38]. CMV glycoprotein B/UL55 has a homology with the U1-70 k protein and can induce anti-U1-70 k antibodies in a mouse model [14,15]. Human vaccination of a live attenuated Towne vaccine, a recombinant CMV glycoprotein B vaccine or a glycoprotein B canarypox vectored vaccine (ALVAC-CMVgB) administered to CMV-seronegative subjects, however, did not induce antinuclear or anti-U1RNP antibodies [16,39]. Reports on the association between autoantibodies to the U1snRNPs and CMV infection in healthy subjects and SLE patients were inconsistent [11,16]. The study reporting a lack of association between anti-snRNP autoantibody production and CMV infection appears credible since they found no anti-U1RNP or anti-Sm positives among healthy individuals and only 2/80 were positive in the anti-U1-70 k ELISA [16]. The other study reported an increased prevalence of CMV infection among healthy individuals with anti-snRNP autoantibodies, however, with unusually high optical densities in the anti-U1RNP ELISA among healthy individuals (mean optical density 0.643 in the CMV(+) group versus 0.406 in the CMV(-) group) and a high prevalence of positive anti-U1RNP among healthy individuals (84% in the CMV(+) group and 24% in the CMV(-) group) [11], making the interpretation of this study difficult. Since we have only two CMV-seronegative SLE patients, our data cannot be compared with these studies.
###end p 62
###begin p 63
###xml 155 156 155 156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 161 162 161 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 26 29 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
###xml 120 123 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 137 145 <span type="species:ncbi:9606">patients</span>
###xml 238 246 <span type="species:ncbi:9606">patients</span>
###xml 276 279 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 361 364 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
In the present study, IgM CMV(+) patients had lower levels of anti-U1RNP/Sm and anti-U1-70 k autoantibodies versus anti-CMV IgM(-)IgG(+) patients (Figures 2 and 3). Anti-snRNPs and other lupus-related autoantibodies were more frequent in patients with high levels of IgG anti-CMV (Table 4). These observations are consistent with the role of immune response to CMV in lupus autoantibody production.
###end p 63
###begin p 64
###xml 186 187 186 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 488 489 488 489 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 494 495 494 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 630 631 630 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 1078 1079 1078 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1356 1358 1356 1358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 55 58 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 241 249 <span type="species:ncbi:9606">patients</span>
###xml 266 269 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 308 311 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 866 869 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 1468 1471 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
The mechanisms of the negative association of IgM anti-CMV and anti-snRNP autoantibodies are unclear. This does not appear to result from a difference in treatment between groups (Table 1); immunosuppressive treatment was not more common in patients of the IgM anti-CMV(+) group versus those of the IgM anti-CMV(-) group. Also, the reduced levels of antibodies in the former group were specific for IgG anti-U1snRNPs and anti-U1-70 k and were not observed in other specificities (Figures 1 and 2). The difference in IgG anti-snRNPs or U1-70 k units that reflect the amount of antibodies in the sera was 30-fold to 80-fold (Figure 2). All of these data suggest that the difference in levels of IgG anti-U1snRNPs and U1-70 k antibodies between groups cannot be a simple reflection of different total IgG levels. It is tempting to speculate that reactivated/reinfected CMV or its products play a role in downregulating anti-snRNP autoantibodies. This may sound strange since most previous studies were focused on the role of viruses in inducing or enhancing autoantibodies in SLE [3]; however, viruses have various mechanisms to inhibit host immune function in order to survive and escape from elimination by the host immune system. In fact, viral anti-inflammatory and immune-modulating proteins have been applied to treat inflammatory and immune disorders [40]. There are several possible mechanisms that may explain inhibition of anti-snRNP autoantibody production by CMV.
###end p 64
###begin p 65
###xml 81 83 81 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 156 158 156 158 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 303 306 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
First of all, U1RNA can stimulate type I interferon (I-IFN) production via TLR7 [41] and anti-snRNP autoantibody production is TLR7 and I-IFN dependent [42,43]. The antagonistic effects of TLR7 and TLR9 stimulation reported recently [44,45] are of particular interest in speculating that the binding of CMV DNA to TLR9 may interfere in the TLR7-dependent anti-snRNP autoantibody production.
###end p 65
###begin p 66
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 112 114 112 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 378 380 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 31 34 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 165 168 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 226 229 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
A second consideration is that CMV has various mechanisms to escape from the attack by a host immune system [46-48], including suppression of I-IFN production [49]. CMV IL-10 or host IL-10 induced by reactivated or reinfected CMV may shift the cytokine balance towards T helper type 2 and show antagonistic effects on IFNgamma-dependent production of anti-snRNP autoantibodies [50].
###end p 66
###begin p 67
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 424 426 424 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 366 369 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 419 422 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 565 573 <span type="species:ncbi:9606">patients</span>
###xml 591 594 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Preferential effects on anti-snRNP autoantibody production are another interesting point that cannot be explained by available information. This situation may not be so unusual, however, considering that the same environmental or endogenous factor can exhibit different effects on different specificities of lupus autoantibodies [51-54]. Any immunological effect of CMV or a combination of the immunological effects of CMV [49] can shift an environment to one unfavorable for production of anti-snRNPs, leading to reduced levels of anti-snRNP autoantibodies in SLE patients with reactivated CMV.
###end p 67
###begin p 68
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 282 290 282 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 52 55 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 153 158 <span type="species:ncbi:10090">mouse</span>
###xml 222 225 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 266 269 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 312 315 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 439 442 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 509 512 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 541 544 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
On the other hand, a strong immune response against CMV proteins may induce or enhance anti-snRNP autoimmune response via molecular mimicry, as shown in mouse models [14,15]. Depending on the balance of immune response to CMV versus the immunosuppressive effects of CMV, therefore, in vivo biological effects of CMV may work towards enhancing or suppressing immune and autoimmune responses. Positive association of high levels of IgG anti-CMV and IgG lupus autoantibodies and negative association of IgM anti-CMV (reflecting reactivation of CMV) and IgG anti-snRNPs antibodies may be consistent with this possibility.
###end p 68
###begin p 69
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 278 280 278 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 455 457 455 457 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 667 668 667 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 623 626 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Coexistence of anti-Su with anti-snRNPs or anti-Ro was also an interesting finding. Like the U1RNA component of snRNPs, the Y RNAs of Ro antigens induce I-IFN via TLR7 stimulation [41]. Anti-snRNPs and anti-Ro are both associated with production of high levels of I-IFN in SLE [55]. The Su antigen was recently identified as Ago2, a component of RNA interference machinery enriched in GW/P bodies containing macromolecular complex with mRNA and microRNA [56]. Anti-Su production in an animal model is also TLR7 dependent, similar to anti-snRNP production [43]. Three autoantibodies that appear to coexist often in the anti-CMV IgM(-)IgG(+) subset of SLE cases (Table 3) are therefore all involved in TLR7 stimulation and/or I-IFN production, suggesting common mechanisms in production.
###end p 69
###begin title 70
Conclusion
###end title 70
###begin p 71
###xml 43 46 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 264 267 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 331 334 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Our findings suggest the potential role of CMV in regulation of autoantibodies to snRNPs and may provide a unique insight to understanding the mechanisms of production of lupus autoantibodies. Longitudinal studies carefully monitoring the kinetics and serology of CMV and autoantibodies will be necessary to understand the role of CMV in lupus autoantibody production.
###end p 71
###begin title 72
Abbreviations
###end title 72
###begin p 73
###xml 5 11 <span type="species:ncbi:9913">bovine</span>
###xml 27 30 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 83 86 <span type="species:ncbi:10376">EBV</span>
###xml 104 107 <span type="species:ncbi:10376">EBV</span>
###xml 109 127 <span type="species:ncbi:10376">Epstein-Barr virus</span>
BSA: bovine serum albumin; CMV: cytomegalovirus; dsDNA: double-stranded DNA; EBNA: EBV nuclear antigen; EBV: Epstein-Barr virus; ELISA: enzyme-linked immunosorbent assay; IFN: interferon; I-IFN: type I interferon; IL: interleukin; mAb: monoclonal antibody; PCR: polymerase chain reaction; RF: rheumatoid factor; SLE: systemic lupus erythematosus; snRNP: small nuclear ribonucleoprotein; TLR: Toll-like receptor; U1-70 k: U1snRNP-70 kDa protein; VCA: viral capsid antigen.
###end p 73
###begin title 74
Competing interests
###end title 74
###begin p 75
The authors declare that they have no competing interests.
###end p 75
###begin title 76
Authors' contributions
###end title 76
###begin p 77
CAPS and MS helped to design the study, perform experiments, and write the manuscript. EKLC designed and expressed recombinant proteins and helped write the manuscript. WCC expressed and purified recombinant proteins. JFMV, GOB, EOR, RENH, MSP and ACC helped to design and perform experiments. MVDM designed the study, performed experiments, and wrote the manuscript. All authors read and approved the final manuscript.
###end p 77
###begin title 78
Acknowledgements
###end title 78
###begin p 79
###xml 107 108 104 105 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
The authors thank Dr Jyunichi Kaburaki (Tokyo Electric Company Hospital, Tokyo, Japan) for his gift of beta2-glycoprotein I, Dr Ger JM Pruijn (Department of Biochemistry, University of Nijmegen, The Netherlands) for providing the full-length U1-70 k protein cDNA, and Dr Pui Y Lee (University of Florida, USA) for his discussion on Toll-like receptors. The present study was supported by CONACyT-SEP Ciencia Basica grant 51353, Universidad de Guadalajara agreement 25473 to MVDM and a grant from Lupus Foundation of America, Inc. to MS. EKLC is supported in part by NIH grant AI47859.
###end p 79
###begin article-title 80
Autoantibodies in systemic lupus erythematosus
###end article-title 80
###begin article-title 81
Systemic lupus erythematosus - is a viral aetiology a credible hypothesis?
###end article-title 81
###begin article-title 82
Viral infection can induce the production of autoantibodies
###end article-title 82
###begin article-title 83
###xml 27 45 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus
###end article-title 83
###begin article-title 84
###xml 0 18 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus
###end article-title 84
###begin article-title 85
###xml 83 88 <span type="species:ncbi:9606">human</span>
Shared early autoantibody recognition events in the development of anti-Sm B/B' in human lupus
###end article-title 85
###begin article-title 86
Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP induce spliceosomme autoimmunity
###end article-title 86
###begin article-title 87
###xml 39 46 <span type="species:ncbi:9986">rabbits</span>
###xml 51 55 <span type="species:ncbi:10090">mice</span>
Lupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments
###end article-title 87
###begin article-title 88
###xml 17 39 <span type="species:ncbi:10335">varicella-zoster virus</span>
###xml 45 63 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Cytomegalovirus, varicella-zoster virus, and Epstein-Barr virus
###end article-title 88
###begin article-title 89
###xml 18 39 <span type="species:ncbi:10359">human cytomegalovirus</span>
Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease
###end article-title 89
###begin article-title 90
Autoimmune response to U1 small nuclear ribonucleoprotein (U1 snRNP) associated with cytomegalovirus infection
###end article-title 90
###begin article-title 91
###xml 0 21 <span type="species:ncbi:10359">Human cytomegalovirus</span>
###xml 25 33 <span type="species:ncbi:9606">patients</span>
Human cytomegalovirus in patients with systemic lupus erythematosus
###end article-title 91
###begin article-title 92
Exacerbation of systemic lupus erythematosus related to cytomegalovirus infection
###end article-title 92
###begin article-title 93
Recombinant cytomegalovirus glycoprotein gB (UL55) induces an autoantibody response to the U1-70 kDa small nuclear ribonucleoprotein
###end article-title 93
###begin article-title 94
###xml 16 20 <span type="species:ncbi:10090">mice</span>
The genotype of mice influences the autoimmune response to spliceosome proteins induced by cytomegalovirus gB immunization
###end article-title 94
###begin article-title 95
Lack of autoantibody production associated with cytomegalovirus infection
###end article-title 95
###begin article-title 96
The 1982 revised criteria for the classification of systemic lupus erythematosus
###end article-title 96
###begin article-title 97
Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices
###end article-title 97
###begin article-title 98
###xml 123 131 <span type="species:ncbi:9606">patients</span>
The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus
###end article-title 98
###begin article-title 99
Autoantibodies against the replication protein A complex in systemic lupus erythematosus and other autoimmune diseases
###end article-title 99
###begin article-title 100
###xml 40 45 <span type="species:ncbi:9606">human</span>
###xml 50 56 <span type="species:ncbi:10090">murine</span>
Distinctive immune response patterns of human and murine autoimmune sera to U1 small nuclear ribonucleoprotein C protein
###end article-title 100
###begin article-title 101
###xml 166 174 <span type="species:ncbi:9606">patients</span>
Quantification of lupus anti-ribosome P antibodies using a recombinant P2 fusion protein and determination of the predicted amino acid sequence of the autoantigen in patients' mononuclear cells
###end article-title 101
###begin article-title 102
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 126 131 <span type="species:ncbi:9606">human</span>
Epitope mapping with a recombinant human 68-kDa (U1) ribonucleoprotein antigen reveals heterogeneous autoantibody profiles in human autoimmune sera
###end article-title 102
###begin article-title 103
Anti-U5 small nuclear ribonucleoprotein(snRNP) antibodies: a rare anti-U snRNP specificity
###end article-title 103
###begin article-title 104
###xml 38 59 <span type="species:ncbi:10359">human cytomegalovirus</span>
###xml 70 78 <span type="species:ncbi:9606">patients</span>
False positive IgM antibody tests for human cytomegalovirus (HCMV) in patients with SLE
###end article-title 104
###begin article-title 105
###xml 24 45 <span type="species:ncbi:10359">human cytomegalovirus</span>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
A longitudinal study of human cytomegalovirus serology and viruria fails to detect active viral infection in 20 systemic lupus erythematosus patients
###end article-title 105
###begin article-title 106
Incidental discovery of high systemic lupus erythematosus disease activity associated with cytomegalovirus viral activity
###end article-title 106
###begin article-title 107
###xml 29 37 <span type="species:ncbi:9606">patients</span>
Cytomegalovirus infection in patients with systemic lupus erythematosus
###end article-title 107
###begin article-title 108
Possible triggering effect of cytomegalovirus infection on systemic lupus erythematosus
###end article-title 108
###begin article-title 109
IgM antibodies against cytomegalovirus in SLE nephritis: viral infection or aspecific autoantibody?
###end article-title 109
###begin article-title 110
###xml 39 47 <span type="species:ncbi:9606">patients</span>
Fatal cytomegalovirus infection in two patients with systemic lupus erythematosus undergoing intensive immunosuppressive therapy: role for cytomegalovirus vigilance and prophylaxis?
###end article-title 110
###begin article-title 111
###xml 36 57 <span type="species:ncbi:10359">human cytomegalovirus</span>
Broadsheet. Number 50: diagnosis of human cytomegalovirus infection and disease
###end article-title 111
###begin article-title 112
###xml 23 31 <span type="species:ncbi:9606">patients</span>
Clinical evaluation of patients with inflammatory connective tissue diseases complicated by cytomegalovirus antigenemia
###end article-title 112
###begin article-title 113
Correlation between cytomegalovirus infection and Raynaud's phenomenon in lupus nephritis
###end article-title 113
###begin article-title 114
###xml 67 85 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure
###end article-title 114
###begin article-title 115
###xml 0 21 <span type="species:ncbi:10359">Human cytomegalovirus</span>
Human cytomegalovirus infection and systemic lupus erythematosus
###end article-title 115
###begin article-title 116
Mixed connective tissue disease
###end article-title 116
###begin article-title 117
###xml 73 78 <span type="species:ncbi:9606">human</span>
The appearance of U1 RNP antibody specificities in sequential autoimmune human antisera follows a characteristic order that implicates the U1-70 kd and B'/B proteins as predominant U1 RNP immunogens
###end article-title 117
###begin article-title 118
###xml 89 92 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
###xml 125 128 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Lack of induction of autoantibody responses following immunization with cytomegalovirus (CMV) glycoprotein B (gB) in healthy CMV-seronegative subjects
###end article-title 118
###begin article-title 119
Viral anti-inflammatory reagents: the potential for treatment of arthritic and vasculitic disorders
###end article-title 119
###begin article-title 120
'Endogenous adjuvant' activity of the RNA components of lupus autoantigens Sm/RNP and Ro 60
###end article-title 120
###begin article-title 121
###xml 54 58 <span type="species:ncbi:10090">mice</span>
Deficiency of the type I interferon receptor protects mice from experimental lupus
###end article-title 121
###begin article-title 122
###xml 50 56 <span type="species:ncbi:10090">murine</span>
TLR7-dependent production of type-I interferon in murine lupus
###end article-title 122
###begin article-title 123
Negative regulation of TLR9-mediated IFN-alpha induction by a small-molecule, synthetic TLR7 ligand
###end article-title 123
###begin article-title 124
Natural and synthetic TLR7 ligands inhibit CpG-A- and CpG-C-oligodeoxynucleotide-induced IFN-alpha production
###end article-title 124
###begin article-title 125
A survival game of hide and seek: cytomegaloviruses and MHC class I antigen presentation pathways
###end article-title 125
###begin article-title 126
Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system
###end article-title 126
###begin article-title 127
###xml 0 21 <span type="species:ncbi:10359">Human cytomegalovirus</span>
Human cytomegalovirus persists in its host and attacks and avoids elimination by the immune system
###end article-title 127
###begin article-title 128
Cytomegalovirus immune evasion
###end article-title 128
###begin article-title 129
###xml 52 56 <span type="species:ncbi:10090">mice</span>
Interferon gamma is required for lupus nephritis in mice treated with the hydrocarbon oil pristane
###end article-title 129
###begin article-title 130
Interleukin 6 dependence of anti-DNA antibody production: evidence for two pathways of autoantibody formation in pristane-induced lupus
###end article-title 130
###begin article-title 131
Fas and Fas ligand mutations inhibit autoantibody production in pristane-induced lupus
###end article-title 131
###begin article-title 132
###xml 78 82 <span type="species:ncbi:10090">mice</span>
Effect of an exogenous trigger on the pathogenesis of lupus in NZB x NZW (F1) mice
###end article-title 132
###begin article-title 133
###xml 25 29 <span type="species:ncbi:10090">mice</span>
X-linked immunodeficient mice spontaneously produce lupus-related anti-RNA helicase A autoantibodies, but are resistant to pristane-induced lupus
###end article-title 133
###begin article-title 134
Association of anti-nucleoprotein autoantibodies with upregulation of type I interferon-inducible gene transcripts and dendritic cell maturation in systemic lupus erythematosus
###end article-title 134
###begin article-title 135
Autoimmune targeting of key components of RNA interference
###end article-title 135

